AU669132B2 - Treating ophthalmic fibrosis using interferon-alpha - Google Patents
Treating ophthalmic fibrosis using interferon-alpha Download PDFInfo
- Publication number
- AU669132B2 AU669132B2 AU27748/92A AU2774892A AU669132B2 AU 669132 B2 AU669132 B2 AU 669132B2 AU 27748/92 A AU27748/92 A AU 27748/92A AU 2774892 A AU2774892 A AU 2774892A AU 669132 B2 AU669132 B2 AU 669132B2
- Authority
- AU
- Australia
- Prior art keywords
- interferon
- international
- document
- page
- lines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010016654 Fibrosis Diseases 0.000 title claims description 14
- 230000004761 fibrosis Effects 0.000 title claims description 14
- 108010047761 Interferon-alpha Proteins 0.000 title description 3
- 102000006992 Interferon-alpha Human genes 0.000 title description 3
- 238000000034 method Methods 0.000 claims description 37
- 238000001356 surgical procedure Methods 0.000 claims description 20
- 230000037390 scarring Effects 0.000 claims description 18
- 108010050904 Interferons Proteins 0.000 claims description 16
- 102000014150 Interferons Human genes 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 229940079322 interferon Drugs 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000010412 Glaucoma Diseases 0.000 claims description 7
- 206010052428 Wound Diseases 0.000 claims description 7
- 208000027418 Wounds and injury Diseases 0.000 claims description 7
- 210000004087 cornea Anatomy 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 6
- 208000002177 Cataract Diseases 0.000 claims description 5
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims description 5
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 5
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims description 5
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims description 5
- 229920002732 Polyanhydride Polymers 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000004127 vitreous body Anatomy 0.000 claims description 4
- 208000001351 Epiretinal Membrane Diseases 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 206010038848 Retinal detachment Diseases 0.000 claims description 2
- 208000014139 Retinal vascular disease Diseases 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 210000001525 retina Anatomy 0.000 claims description 2
- 230000004264 retinal detachment Effects 0.000 claims description 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- 229920013641 bioerodible polymer Polymers 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940000033 dermatological agent Drugs 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 229940047124 interferons Drugs 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 206010036346 Posterior capsule opacification Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 229940065638 intron a Drugs 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229960003943 hypromellose Drugs 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000031472 Retinal fibrosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000018594 Tumour necrosis factor Human genes 0.000 description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- -1 hydromesterone Chemical compound 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- XKOKMMJQERSMET-UHFFFAOYSA-N B(O)(O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O Chemical compound B(O)(O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(CC(O)(C(=O)O)CC(=O)O)(=O)O XKOKMMJQERSMET-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FDEQQCOTLPPCAO-UHFFFAOYSA-N Cl.OC(O)=O Chemical compound Cl.OC(O)=O FDEQQCOTLPPCAO-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010067776 Ocular pemphigoid Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 235000013703 Telopea speciosissima Nutrition 0.000 description 1
- 244000228098 Telopea speciosissima Species 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940031955 anhydrous lanolin Drugs 0.000 description 1
- 230000002022 anti-cellular effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- ISQINHMJILFLAQ-UHFFFAOYSA-N argon hydrofluoride Chemical compound F.[Ar] ISQINHMJILFLAQ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001760 tenon capsule Anatomy 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
OP1 DAIE 03/05/93 AOJP DATE 08/07/93 APPLN. ID 27748/92 PCT NUMBER PCT/AU92/00541 11I 1111 111 11111111111111111111 111 AU9227748 IN IKNA I UNAL APIPLICA IUN 1UBLIbHt- U UNUEbK IL VIA bNI N UPLIA I IUN I IKhA 1 Y ('CT) (51) International Patent Classification 5 (11) International Publication Number: WO 93/06856 A61K 37/66 Al (43) International Publication Date: 15 April 1993 (15.04,93) (21) International Applic..,,i Number: PCT/AU92/00541 (81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, (22) International Filing Date: 12 October 1992 (12.10.92) MN, MW, NL, NO, PL, RO, RU, SD, SE, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF.
Priority data: CG, CI, CM, GA, GN, ML, MR, SN TD, TG).
PK 8865 11 October 1991 (11.10.91) AU PK 9080 22 October 1991 (22.10.91) AU Published With international search report.
(71)(72) Applicants and Inventors: GILLIES, Mark, Cedric [AU/AU]; 18 Waratah Aenue, Randwick, NSW 2031 MORLET, Nigel [AU/AU]; 2/13 Bell Street, Watsons Bay, NSW 2030 SAROSSY, Marc, George (AU/AU]; 46 Green Street, Narrabundah, ACT 2604
(AU).
(74) Agent: SPRUSON FERGUSON; G.P.O. Box 3898, Sydney, NSW 2001 (AU).
(54)Title: TREATING OPHTHALMIC FIBROSIS USING INTERFERON-ALPHA (57) Abstract The present invention relates to the use of topical interferon-a for the treatment of various forms of fibrosis in and around the eye arising from various ophthalmic diseases and procedures. Specifically the invention relates to alleviation of corneal scarring after laser photoablative refractive keratectomy (PRK). It aslo relates to the alleviation of posterior (lens) capsular opacification after extracapsular cataract surgery with lens implant; the alleviation of wound scarring following glaucoma filtration surgery. Interferon-a may also be used to coat the lens implant prior to or during implantation. It may also possibly be injected into the eye during eye surgery for inhibiting posterior capsule opacification after cataract surgery and in addition may be injected into the vitreous body to prevent retinal fibrosis and proliferative vitreo-retinopathy, and injected subconjunctivally to inhibit fibrosis and scarring following glaucoma filtration surgery.
WO 93/06856 PCT/AU92/00541 1 TREATING OPHTHALMIC FIBROSIS USING INTERFERON-ALPHA Technical Field The present invention relates to the use of topical interferon-a for the treatment of various forms of fibrosis in and around the eye arising from various ophthalmic diseases and procedures. Specifically the invention relates to alleviation of corneal scarring after laser photoablative refractive keratectomy (PRK). It also relates to the alleviation of posterior (lens) capsular opacification after extracapsular cataract surgery with lens implant; the alleviation of wound scarring following glaucoma filtration surgery.
Interferon-ot may also be usd to coat the lens implant prior to or during implantation. It may also possibly be injected into the eye during eye surgery for inhibiting posterior capsule opacification after cataract surgery and in addition may be injected into the vitreous body to prevent retinal fibrosis and proliferative vitreo-retinopathy, and injected subconjunctivally to inhibit fibrosis and scarring following glaucoma filtration surgery.
Background Art In the field of ophthalmic surgery, it is known to use excimer laser photoablative refractive keratectomy to sculpt the cornea of the eye in order to relieve refractive errors myopia) and a number of corneal conditions and diseases. Specifically, the 193nm argon fluoride excimer laser is able to discretely remove corneal tissue by photoablation without thermal damage to surrounding tissue.
Of major concern is the activation of the stromal keratocytes when a wound is made to the stroma. As is well known, the basic response of wounded tissue is to repair the defect and therefore the ophthalmic surgeon when using this technique is confronted with alteration to the biochemistry, morphologic features and tissue function unpredictability brought about by the wound itself and the healing phenomenon.
Therefore, even though excimer laser ablation of corneal tissue appears to be an efficient method of removing tissue with minimal damage to adjacent areas, nevertheless the healing process does not always lead to the preservation of transparent corneal tissue.
Previous methods of overcoming this problem have been: application of topical steroids such as prednisolone, prednisolone acetate, prednisolone sodium phosphate, fluoromethalone, fluoromethalone acetate, hydromesterone, dexamethasone, and dexamethasone alcohol. Other compounds tested have been idoxuridine, collagen crosslinkage inhibitors and mitomycin C.
It is an object of this invention to ameliorate the known disadvantages of present techniques when dealing with the wound repair mechanism following photoablative refractive keratectomy.
Interferons are a heterogeneous group of proteins that can inhibit many aspects of the fibrotic response. Originally identified by their well known ability to interfere with the production of viral RNA and protein, they also exert anticellular activities generally considered to be inhibitory, which maybe due to their ability to inhibit the c-myc proto- WO 93/06856 PCI/A U92/00541 2 oncogene. Type I interferon (viral interferon, interferon-a and is produced in response to viral infection, and type II (immune interferon, interferon-y) in response to specific antigens or mitogens. Of the different classes, a-interferon is secreted by leukocytes, P- by fibroblasts and 7- by stimulated lymphocytes. Interferons, particularly interferon-a, have been successfully used in humans for twenty years for the treatment of systemic malignancy.
Considerable interest has recently been shown in the potential of interferon as a treatment for such fibrotic diseases as systemic sclerosis, pulmonary fibrosis and keloid.
Fibroblasts are stimulated to produce interferons by many cytokines that mediate wound healing, such as interleukin-l-(IL-1), platelet derived growth factor (PDGF) and tumour necrosis factor (TNF). Interferons inhibit fibroblast chemotaxis and proliferation as well as collagen production, the latter synergistically with TNF-c. Intraperitoneally implanted foreign bodies in mice suffered less encapsulation in the presence of interferon-y, the capsules having a reduced collagen content. Fibroblast glycosaminoglycan production is inhibited by interferon-a, while collagenase production is increased. This deactivation of activated fibroblasts can persist for a long time after a brief exposure to interferon. Of the different types of interferon, the a- and Psubclasses exhibit a broader antifibrotic spectrum.
The present inventors have recently demonstrated that interferon-o inhibits foetal calf serum and platelet derived growth factor induced proliferation of human tenon's capsule fibroblasts in vitro. They suggest that interferons may prove to be of benefit in the treatment of fibrosis following PRK in particular, and of ocular fibrosis in general.
Disclosure of the Invention According to a first form of this invention, there is provided a method for the treatment of corneal scarring in a patient requiring such treatment, comprising administering to the cornea of said patient an effective amount of interferon-a or a pharmaceutical composition for the treatment of corneal scarring in a patient comprising interferon-c together with a pharmaceutically acceptable carrier, diluent and/or excipient.
According to a second form of this invention, there is provided a method for inhibiting opacification of the posterior capsule after extracapsular cataract surgery, in a patient requiring such treatment, comprising administering to the lens capsule of said patient an effective amount cf interferon-a or a pharmaceutical composition for this method comprising interferon-c together with a pharmaceutically acceptable carrier, diluent and/or excipient.
According to a third form of this invention, there is provided a method for inhibiting wound fibrosis and scarring after glaucoma filtration surgery, in a patient requiring such treatment, comprising administering to the subconjunctival space of said patient an effective amount of interferon-a or a pharmaceutical composition for this WO 93/06856 PCT/A U92/00541 3 method comprising interferon-at together with a pharmaceutically acceptable carrier, diluent and/or excipient.
According to a fourth form of this invention, there is provided a method for inhibiting formation of pre-retinal membranes and proliferative vitreo-retinopathy foiiowing retinal detachment surgery and/or vitrectomy, following trauma, and as a result of retinal vascular disease (including diabetes, thalassaemia and retinal vein occlusion) in a patient requiring such treatment, comprising administering to the vitreous body or retina of said patient an effective amount of interferon-ca or a pharmaceutical composition for this method comprising interferon-a together with a pharmaceutically acceptable carrier, diluent and/or excipient.
Interferon-c 2A, interferon-a 2B or interferon-x 2C or any other type of interferon-cx may be used in this invention.
The invention also provides novel protein formulations in which the carrier or diluent is a bioerodable polymer, e.g. a polymer of a polyanhydride which may be a copolymer of sebacic acid and bis paracarboxyphenoxybutane; or a poly(ortho) ester.
The method of this invention inhibits the scarring response following a variety of corneal procedures such as photoablative refractive keratectomy; lamellar keratoplasty; lamellar keratectomy; epikeratoplasty; removal of pterygium and keratomileusis.
Typically, the patient on whom the methods of this invention are used is a human.
However, the methods would also be able to be used on other mammals.
The methods of this invention may also inhibit scarring after chemical damage to conjunctiva and cornea and may also prevent scarring in pathological conditions such as ocular pemphigoid and StevensJohnson's syndrome, Simplex Zoster keratitis. It may also inhibit fibrosis in thyroid eye disease, orbital psuedo-tumour and ocular myositis.
Preparation of topical composition drops are made up from Intron A powder (Schering-Plough) or Roferon-A (Roche) to a solution of 1 x 106 IU/mL.
Formulation of Intron A is as follows: a- 2b interferon solution Dibasic sodium phosphate, anhydrous, USP Monoscdium phosphate, monohydrate, USP Glycine, ph. eur.
Human albumin solution, ph. eur.
Water for injection, ph. eur.
D us base may be hypromellose or polyvinyl alcohol for dilution to 106 IU/mL.
The composition of the present invention may be administered topically as a solution, ointment, or within a collagen shield or similar dissolving corneal contact protective dressing containing conventional, non-toxic, pharmaceutically aczeptable carriers, diluents and/or excipients as desired, or by direct injection.
t1 The dosage range of interferon-a may be between about 50,000 and 50 x 106 IU WO 93/06856 PCT/AU92/00541 4 and may be between about 1 x 106 to 20 x 106 IU/mL. Preferably the dosage is between about lx106 and about 10x106 IU/mL. The interferon-cx may be administered in 50 pL drops, four times a day for six weeks; or preferably two times a day for one week.
Interferon-o may also be administered two times a day for three days or one drop hourly for three days. This dosage range is applicable to the first, second and third embodiments of the invention.
When applied according to the fourth embodiment the interferon-ca is given by intravitreal injection within the range of 50,000 to 5.0 x 106 IU/0. mL.
The compositions of this invention may also contain a slow release polymer.
The pharmaceutically acceptable carriers, diluents and/or excipients are those well known in the art of ophthalmic surgery and comprise the following: hydroxyethyl cellulose, hypromellose, polyvinyl alcohol, gelatin, polyquad, dextran, castor oil or other vegetable oil e.g. sesame, inert soft white paraffin, liquid paraffin, anhydrous lanolin, sodium hyalusonate, methyl cellulose, potassium sorbate, polysorbate; or sodium chloride, sodium phosphate, buffers hydrochloric acid bicarbonate, Na citrate (citric acid) boric acid in purified water. They may also be biodegradable polymer esters (polyanhydrides) e.g. sebacic acid and bis paracarboxyphenoxybutane, which are employed in the novel formulations of the invention.
The compositions may also contain preservatives and antiseptics such as: thiomersal, phenyl mercuric acetate, benzylalkonium chloride, disodium edetate, sodium metabisulfite, polymercuric nitrate, chlorobutol, hyloxapol, povidone, propyl hydroxy benzoate, methyl hydroxy benzoate.
It is preferable that the composition of this invention be applied to the cornea immediately following photoablative refractive keratectomy. As a drop, ointment or collagen shield etc. Where the interferon is applied as a drop, it is preferably to treat the eye thus, four to eight times a day for up to about 6 weeks.
The corneal response may be modified by the pre-treatment with interferon at drops before PRK. It may also be modified by pre-treatment with steroid drops.
The interferon-a may be prepared from natural sources or may be prepared by recombinant DNA techniques. All of these techniques would be well known to one skilled in this art.
Best Mode and Other Modes for Carrying Out the Invention An effective amount of interferon-a-2b to prevent corneal scarring after photoablative refractive keratectomy is administered topically to the cornea which has been subjected to this procedure.
The present invention will now be described with reference to the following examples which should not be construed as limiting on the scope thereof.
WO 93/06856 PCT/AU92/00541 Example 1 Preparation of interferon a-2B topical composition Preparation of topical composition drops are made ip from Intron A powder (Schering-Plough) to a solution of 1 x 106 IU/mL.
Formulation of Intron A is as follows: a-2b interferon solution Dibasic sodium phosphate, anhydrous, USP Monosodium phosphate, monohydrate, USP Glycine, ph. eur.
Human albumin solution, ph. eur.
Water for injection, ph. eur.
The drops base is hypromellose or polyvinyl alcohol for dilution to 106 IU/mL.
Example 2 The composition of this invention is applied to the cornea immediately following photoablative refractive keratectomy, As a drop, ointment or collagen shield etc. Where the interferon is applied as a drop, it is preferable to treat the eye thus, four times a day for up to about 6 weeks.
The corneal response may be modified by the pre-treatment with interferon-ca-2b drops before PRK. It may also be modified by pre-treatment with steroid drops.
Industrial Applicability It should be clear that the method of treatment of this invention will find wide use in the veterinary and medical fields.
The foregoing describes only some embodiments of the present invention and modifications obvious to those skilled in the art can be made thereto without departing from the scope of the invention.
References Gipson IK (1990) Archives of Opthalmology 108 1539.
Cintron C (1990) Archives of Opthalmology 108 1540.
Binder PS (1990) Archives of Opthalmology 108 1541.
Claims (15)
1. Use of interferon-a for treating corneal scarring, for inhibiting opacification of the posterior capsule after extracapsular cataract surgery, for inhibiting wound fibrosis and scarring after glaucoma filtration surgery, or for inhibiting formation of pre-retinal membranes and proliferative vitreo-retinopathy.
2. Use according to claim 1 wherein the dosage of interferon-c is between about 50,000 and 50 x 106 IU/mL.
3. Use according to claim 2 wherein the dosage unit is between about 1 x 106 to x 106 IU/mL.
4. Use according to claim 3 wherein the dosage range is between about 1 x 106 and about 10 x 106 IU/mL. Use according to any one of claims 1 to 4 wherein the interferon-a is interferon-a-2A.
6. Use according to any one of claims 1 to 4 wherein interferon-a is interferon- a-2B.
7. Use according to any one of claims 1 to 4 wherein interferon-c is interferon- a-2C.
8. A process for preparing a composition of interferon-a comprising formulating interferon-a together with a pharmaceutically acceptable carrier in the form of a S 20 bioerodible polymer of a polyanhydride ester or a poly(ortho) ester.
9. The process of claim 8 wherein the polyanhydride is a copolymer of sebacic acid and bisparacarboxyphenoxybutane. A method for the treatment of corneal scarring in a patient requiring such treatment, comprising administering to the cornea of said patient an effective amount of interferon-a or a pharmaceutical composition for the treatment of corneal scarring in a patient comprising interferon-a together with a pharmaceutically acceptable carrier, diluent and/or excipient. •11. A method for inhibiting opacification of the posterior capsule after extracapsular cataract surgery, in a patient requiring such treatment, comprising administration to the lens capsule of said patient an effective amount of interferon-a or a pharmaceutical composition for this method comprising interferon-a together with a pharmaceutically acceptable carrier, diluent and/or excipient.
12. A method for inhibiting wound fibrosis and scarring after glaucoma filtration surgery, in a patient requiring such treatment, comprising administering to the ,bconjunctival space of said patient an effective amount of interferon-a or a pharmaceutical composition for this method comprising interferon-a together with a pharmaceutically acceptable carrier, diluent and/or excipient.
13. The method according to any one of claims 10 to 12 wherein the dosage of interferon-a range is between about 50,000 and 50 x 106 IU/mL. [N:\LIBuu]00701:KEH
14. The method according to claim 13 wherein the dosage unit is between about 1 x 106 to 20 x 106 IU/mL. The method according to claim 14 wherein the dosage range is between about 1 x 106 and about 10 x 106 IU/mL.
16. The method according to any one of claims 12 to 15 wherein the interferon-a may be administered in about 50uL drops four times a day for six weeks.
17. The method according to claim 16 wherein the interferon-a may be administered two times a day for three days.
18. The method according to any one of claims 12 to 15 wherein the interferon-a is administered as one drop hourly for three days.
19. A method for inhibiting formation of pre-retinal membranes and proliferative vitreo-retinopathy following retinal detachment surgery and/or vitrectomy, following trauma, and as a result of retinal vascular disease (including diabetes, thalassaemia and retinal vein occlusion) in a patient requiring such treatment, comprising administering to is the vitreous body or retina of said patient an effective amount of interferon-a or a pharmaceutical composition for this method comprising interferon-a together with a pharmaceutically acceptable carrier, diluent and/or excipient. The method according to claim 19 wherein the interferon-a range is given by intravitreal injection within the range of about 50,000 to 5.0 x 106 IU/0.lmL. Dated 8 March, 1996 Mark Cedric Gillies Nigel Morlet Marc George Sarossy Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON [N:\LIBuul00701:KEH INTERNATIONAL SEARCH REPORT International application No. PCT/AU92/00541 A. CLASSIFICATION OF SUBJECT MATTER Int. Cl. 5 A61K 37/66 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC A61K 37/66 45/02 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU: IPC as above Electronic data base consulted during the international search (name of data base, and where practicable, search terms used) DERWENT: ALPHA CAS: INTERFERON AND ALPHA AND FIBROSIS OR OPHTHALMIC OR EYE OR OCULAR OR RETINAL C. DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to Claim No. AU,B, 68201/90 (630530) (BAKER CUMMINS DERMATOLOGICALS, INC) 14 March 1991 (14.03.89). Page 10 lines 23- X Page 11 lines 23-28 8 Y Page 11 lines 27-28 1-4, 12-22 AU,B, 68292/87 (601712) (DR KARL THOMAE GESELLSCHAFT MIT BESCHRANKTERHAFTUNG) 6 August 1987 (06.08.87) X Page 8 lines 28-37 8, 9 Y Page 6 lines 33-36 1-4, 12-22 Further documents are listed See patent family annex. in the continuation of Box C.y Special categories of cited documents later document published after the international filing date or pnority date and not in conflict document defining the eneral state of the art which is with the application ut cited to understand the not considered to be o particular relevance principle or theory underlying the invention earlier document but published on or after the document of particular retevance; the claimed international filing date invention cannot be considered novel or cannot be document which may throw doubts on priority claim(s) considered to involve an inventive step when the or which is cited to establish the publication date of document is taken alone another citation or other special reason (as specified) document of particular relevance; the claimed document referring to an oral disclosure, use, invention cannot be considered to involve an exhibition or other means inventive step when the document is combined document published prior to the international filing date with one or more other such documents, such but later than the priority date claimed combination being obvious to a person skilled in the art document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 24 November 1992 (24.11.92) 2 p /q1.2 q. Name and mailing address of the ISA/AU Ahorized officer AUSTRALIAN PATENT OFFICE PO BOX 200 WODEN ACT 2606 AUSTRALIA -JON G HANSON Facsimile No. 06 2853929 Telephone No. (G6) 2832262 Form PCT/ISA/210 (continuation of first sheet (July 1992) copbko INTERNATIONAL SEARCH REPORT International applicatiun No. PCTIAU92/00541 C(Continuation). DOCUMENTS CONSIDERED TO BIE RELEVANT Category* Citation of document, with indication, where appropriate of the relevant passages Relevant to Claim No. AU,B, 77307/87 (590958) (DR KARL THOMAB GESELLSCHAFT MIT BESCHRANKTERHAFTUNG) 25 February 1988 (25.02.88) X Page 2 lines 28-33 8 Y Page 1A lines 13-13 1-4, 12-22 WO,A, 88/03411 (AMARILLO CELL CULTURE COMPANY, INC) 19 May 1988 (19.05.88) X Page 12 lines 4-6 8 Y Page 7 lines 13-22 1-4, 12-22 EPA, 82481 (SCHERING CORP) 29 June 1983 (29.06.83) X Page 2 lines 7-12 8 A i Foirn PCT/ISA/210 (continuation of second shect)(July 1992) copbko INTERNA IONAL SEARCH REPORT International application No. PCT/AU92/00541 Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet) This international search report has not established in respect of certain claims under Article 17(2)(a) for the following reasons: 1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: 2. Claim Nos.: because they relate to parts of the international application that do not comply with the S prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: 3. Claims Nos.: S because they are dependent c.,'ns and are not drafted in accordance with the second and third sentences of Rule 6.4(a). Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: 1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims 2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee, 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 4. No required additional search fees were timely paid by the applicant, Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: Remark on Protest 7 The additional search fees were accompanied by the applicant's protest. S No protest accompanied the payment of additional search fees. Form PCT/ISA/210 (continuation of first sheet(1))(July 1992) copbko INTERNATIONAL SEARCH REPORT Information on patent family memb, International anpplicatio. No. PCT/AU92/00541 This Annex lists the known publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information. Patent Document Cited in Search Patent Family Member SReport AU 630530 DE 3019761 GB 2051521 JP 55161457 AU 601712 DE 3603444 EP 231816 AU 590958 DE 3628468 EP 258683 US 4824674 WO 88/03411 EP 341258 US 5019382 EP 82481 DE 3262575 EP 82481 END OF ANNEX Form PCT/ISA/210(patcnt family annex)(July 1992) copbkc
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU27748/92A AU669132B2 (en) | 1991-10-11 | 1992-10-12 | Treating ophthalmic fibrosis using interferon-alpha |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPK886591 | 1991-10-11 | ||
| AUPK8865 | 1991-10-11 | ||
| AUPK9080 | 1991-10-22 | ||
| AUPK908091 | 1991-10-22 | ||
| PCT/AU1992/000541 WO1993006856A1 (en) | 1991-10-11 | 1992-10-12 | Treating ophthalmic fibrosis using interferon-alpha |
| AU27748/92A AU669132B2 (en) | 1991-10-11 | 1992-10-12 | Treating ophthalmic fibrosis using interferon-alpha |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2774892A AU2774892A (en) | 1993-05-03 |
| AU669132B2 true AU669132B2 (en) | 1996-05-30 |
Family
ID=27153109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU27748/92A Ceased AU669132B2 (en) | 1991-10-11 | 1992-10-12 | Treating ophthalmic fibrosis using interferon-alpha |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU669132B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995013827A1 (en) * | 1993-11-19 | 1995-05-26 | The University Of Sydney | A method for preventing or controlling cataract |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0082481A1 (en) * | 1981-12-23 | 1983-06-29 | Schering Corporation | Stabilised alpha-interferon formulations and their preparation |
| WO1988003411A1 (en) * | 1986-11-06 | 1988-05-19 | Amarillo Cell Culture Company, Inc. | Improved interferon therapy |
| AU6820190A (en) * | 1988-01-25 | 1991-03-14 | Baker Norton Pharmaceuticals, Inc. | Method of treating fibrotic disorders |
-
1992
- 1992-10-12 AU AU27748/92A patent/AU669132B2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0082481A1 (en) * | 1981-12-23 | 1983-06-29 | Schering Corporation | Stabilised alpha-interferon formulations and their preparation |
| WO1988003411A1 (en) * | 1986-11-06 | 1988-05-19 | Amarillo Cell Culture Company, Inc. | Improved interferon therapy |
| AU6820190A (en) * | 1988-01-25 | 1991-03-14 | Baker Norton Pharmaceuticals, Inc. | Method of treating fibrotic disorders |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995013827A1 (en) * | 1993-11-19 | 1995-05-26 | The University Of Sydney | A method for preventing or controlling cataract |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2774892A (en) | 1993-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5811446A (en) | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor | |
| Freeman et al. | Prevalence, pathophysiology, and treatment of rhegmatogenous retinal detachment in treated cytomegalovirus retinitis | |
| Dana et al. | Topical interleukin 1 receptor antagonist promotes corneal transplant survival1 | |
| AU737312B2 (en) | Treatment and prevention of adhesions | |
| CA2498191A1 (en) | Method of inhibiting choroidal neovascularization | |
| ZA200503975B (en) | Use of rimexolone in the treatment of dry eye | |
| AU674335B2 (en) | Ophthalmological preparation | |
| EP0434625B1 (en) | IGF-I for treating adverse effect of steroid therapy | |
| SK284371B6 (en) | Use of ophthalmic composition containing active amount of topical carbonic anhydrase inhibitor for the manufacture of a medicament | |
| JPH0930966A (en) | New pharmaceutical preparation for eye | |
| JPH0561254B2 (en) | ||
| AU7846894A (en) | Compositions containing growth factors and antiplastic agents | |
| AU669132B2 (en) | Treating ophthalmic fibrosis using interferon-alpha | |
| US5863530A (en) | Treating ophthalmic fibrosis using interferon-α | |
| WO1993006856A1 (en) | Treating ophthalmic fibrosis using interferon-alpha | |
| US6562829B1 (en) | Treatment of hepatic cirrhosis | |
| JPH06271478A (en) | Agent for treating dry eye | |
| EP0080032A2 (en) | Pharmaceutical preparation for treating herpetic lesions | |
| MXPA04008776A (en) | Agents for corneal or intrastromal administration to treat or prevent disorders of the eye. | |
| Swan et al. | Mycotic endophthalmitis caused by Penicillium sp. after parenteral drug abuse | |
| Gillies et al. | Glaucoma filtering surgery with interferon-α-2b | |
| EP3338792A1 (en) | Corneal damage prevention/treatment composition comprising thymosin beta 4 and citric acid as active ingredients | |
| US5721206A (en) | Pharmaceutical composition for use as a retinal pigment epithelial cell growth agent | |
| WO2013148155A1 (en) | Compositions and methods for the treatment of dry eye disease | |
| EP0795333A2 (en) | TGF-beta regulating substance for treatment of myopia or hyperopia |